Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Retension Pharmaceuticals announces its Initial Public Offering, pricing 3,750,000 shares at $12.00 each, raising $45 million. The offering is set to close around October 13, 2026, to support clinical trials.
Amount Raised
$45 Million
Round Type
Post-IPO Equity
Falls ChurchBiotechnologyHealthcareHealth CareInvestors
Description
Retension Pharmaceuticals, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) at $12.00 per share for 3,750,000 shares. The gross proceeds from the IPO are expected to total $45 million. The funds will primarily be used to advance Phase 2b and Phase 3 clinical trials of its hypertension treatment, RTN-001. Trading is expected to commence on October 9, 2026, on the Nasdaq Capital Market.
Fundz sees it the moment Retension Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Retension Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.